These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30167098)

  • 21. NMO spectrum disorders comprise the major portion of CNS inflammatory diseases in Thai patients: A cross sectional study.
    Apiwattanakul M; Kasemsuk C
    Mult Scler Relat Disord; 2014 Jan; 3(1):61-6. PubMed ID: 25877974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria.
    Papeix C; Beigneux Y; Maillart E; de Seze J; Lubetzki C; Vukusic S; Collongues N; Marignier R
    Eur J Neurol; 2020 Nov; 27(11):2250-2256. PubMed ID: 32559008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
    Chan KH; Ramsden DB; Yu YL; Kwok KH; Chu AC; Ho PW; Kwan JS; Lee R; Lim E; Kung MH; Ho SL
    Eur J Neurol; 2009 Mar; 16(3):310-6. PubMed ID: 19138340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings.
    Duan T; Verkman AS
    Brain Pathol; 2020 Jan; 30(1):13-25. PubMed ID: 31587392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromyelitis optica-IgG testing in an Indian cohort with neuromyelitis optica and related demyelinating disorders: Our experience.
    Unni N; Barhate K; Ahmad N; Ganeshan M; Singhal B
    Ann Indian Acad Neurol; 2013 Jul; 16(3):376-9. PubMed ID: 24101820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica.
    Tasaki A; Shimizu F; Sano Y; Fujisawa M; Takahashi T; Haruki H; Abe M; Koga M; Kanda T
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):419-30. PubMed ID: 24259591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of claims-based diagnoses of adult and pediatric neuromyelitis optica spectrum disorder and variations in diagnostic evaluation and treatment initiation.
    Gmuca S; Hardy DI; Narula S; Stoll S; Harris J; Zhao Y; Xiao R; Weiss PF; Waldman AT; Gerber JS
    Mult Scler Relat Disord; 2020 Jan; 37():101488. PubMed ID: 31706167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
    Magaña SM; Pittock SJ; Lennon VA; Keegan BM; Weinshenker BG; Lucchinetti CF
    Arch Neurol; 2009 Aug; 66(8):964-6. PubMed ID: 19667216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Asseyer S; Schmidt F; Chien C; Scheel M; Ruprecht K; Bellmann-Strobl J; Brandt AU; Paul F
    Mult Scler J Exp Transl Clin; 2018; 4(3):2055217318796684. PubMed ID: 30186620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resolution of inflammation in neuromyelitis optica spectrum disorders.
    Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
    Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NMO-IgG Induce Interleukin-6 Release via Activation of the NF-κB Signaling Pathway in Astrocytes.
    Wang Y; Zhang J; Chang H; Wang H; Xu W; Cong H; Zhang X; Liu J; Yin L
    Neuroscience; 2022 Aug; 496():96-104. PubMed ID: 35659638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of neuromyelitis optica spectrum disorders - An update.
    Bruscolini A; Sacchetti M; La Cava M; Gharbiya M; Ralli M; Lambiase A; De Virgilio A; Greco A
    Autoimmun Rev; 2018 Mar; 17(3):195-200. PubMed ID: 29339316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
    Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
    J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
    Mader S; Jeganathan V; Arinuma Y; Fujieda Y; Dujmovic I; Drulovic J; Shimizu Y; Sakuma Y; Stern JNH; Aranow C; Mackay M; Yasuda S; Atsumi T; Hirohata S; Diamond B
    Arthritis Rheumatol; 2018 Feb; 70(2):277-286. PubMed ID: 29073350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification].
    Aktas O; Kümpfel T
    Nervenarzt; 2021 Apr; 92(4):307-316. PubMed ID: 33728474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.